MPA
MCID: MCR088
MIFTS: 58

Microscopic Polyangiitis (MPA)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 53 59 37
Microscopic Polyarteritis 59 73
Micropolyangiitis 59
Mpa 59

Characteristics:

Orphanet epidemiological data:

59
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Microscopic Polyangiitis

NIH Rare Diseases : 53 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to vasculitis and anca-associated vasculitis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and kidney, and related phenotypes are nausea and vomiting and arthritis

Wikipedia : 76 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 vasculitis 32.3 HLA-B MPO TNF
2 anca-associated vasculitis 32.2 HLA-DRB1 MPO TNF
3 granulomatosis with polyangiitis 30.7 FCGR3B MPO
4 churg-strauss syndrome 30.5 IL10 MPO TNF
5 temporal arteritis 30.1 HLA-DRB1 TNF
6 endocarditis 30.1 IL10 TNF
7 lung disease 30.0 IL10 MPO TNF
8 eosinophilic granulomatosis with polyangiitis 29.9 FCGR3B MPO
9 hypersensitivity vasculitis 29.8 HLA-DRB1 MPO
10 cytomegalovirus infection 29.8 HLA-B TNF
11 central nervous system vasculitis 29.8 HLA-DRB1 TNF
12 aspergillosis 29.7 IL10 TNF
13 chlamydia 29.7 IL10 TNF
14 pneumonia 29.7 IL10 MPO TNF
15 arthritis 29.7 HLA-DRB1 IL10 TNF
16 colitis 29.7 IL10 MPO TNF
17 cholangitis 29.5 HLA-B HLA-DRB1 TNF
18 takayasu arteritis 29.5 HLA-B HLA-DRB1 TNF
19 appendicitis 29.5 IL10 MPO TNF
20 mixed connective tissue disease 29.5 HLA-DRB1 IL10 TNF
21 connective tissue disease 29.5 HLA-DRB1 IL10 TNF
22 multiple sclerosis 29.5 HLA-DRB1 IL10 TNF
23 graft-versus-host disease 29.4 HLA-B HLA-DRB1 IL10 TNF
24 rheumatoid arthritis 29.4 HLA-B HLA-DRB1 IL10 TNF
25 sclerosing cholangitis 29.3 HLA-B HLA-DRB1 MPO TNF
26 asthma 29.2 HLA-DRB1 IL10 MPO TNF
27 systemic lupus erythematosus 28.8 FCGR3B HLA-DRB1 IL10 MPO TNF
28 polyarteritis nodosa, childhood-onset 10.5
29 polyarteritis nodosa 10.5
30 allergic angiitis 10.4
31 macrophagic myofasciitis 10.3
32 glomerulonephritis 10.3
33 pulmonary fibrosis 10.3
34 breast cancer 10.2
35 neuropathy 10.2
36 bronchitis 10.2 MPO TNF
37 autoimmune inner ear disease 10.1 MPO TNF
38 inner ear disease 10.1 MPO TNF
39 juvenile rheumatoid arthritis 10.1 HLA-DRB1 TNF
40 diffuse alveolar hemorrhage 10.1
41 periodontosis 10.1 MPO TNF
42 postherpetic neuralgia 10.1 HLA-B HLA-DRB1
43 granulocytopenia 10.1 MPO TNF
44 hypersensitivity reaction type iii disease 10.1 MPO TNF
45 idiopathic inflammatory myopathy 10.1 HLA-B HLA-DRB1
46 beryllium disease 10.1 HLA-DRB1 TNF
47 chronic beryllium disease 10.1 HLA-DRB1 TNF
48 pars planitis 10.1 HLA-B HLA-DRB1
49 spondyloarthropathy 1 10.1 HLA-B TNF
50 pityriasis rosea 10.1 HLA-B HLA-DRB1

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

59 32 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
2 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
3 renal insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0000083
4 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
5 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
6 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
7 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
8 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
9 sinusitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000246
10 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
11 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
12 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
13 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
14 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001733
15 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
16 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
17 glomerulopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0100820
18 abnormality of the retinal vasculature 59 32 occasional (7.5%) Occasional (29-5%) HP:0008046
19 hematuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0000790
20 hemoptysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002105
21 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
22 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
23 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
24 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
25 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
26 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
27 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
28 subcutaneous hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0001933
29 gastrointestinal infarctions 59 32 frequent (33%) Frequent (79-30%) HP:0005244
30 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
31 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
32 peritonitis 59 32 frequent (33%) Frequent (79-30%) HP:0002586
33 uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000554
34 episcleritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100534
35 oliguria 59 32 hallmark (90%) Very frequent (99-80%) HP:0100520
36 peripheral neuropathy 59 Occasional (29-5%)
37 increased inflammatory response 59 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
3
alemtuzumab Approved, Investigational Phase 4,Phase 1 216503-57-0
4
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
6
Methotrexate Approved Phase 4,Phase 3,Phase 2 59-05-2, 1959-05-2 126941
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3 2921-57-5
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
10
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 53-03-2 5865
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
14
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3 2920-86-7
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 4,Phase 3,Phase 2
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Vitamin B9 Phase 4,Phase 3,Phase 2
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 4,Phase 3,Phase 2
26 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
27 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
28 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
31 Folate Phase 4,Phase 3,Phase 2
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
33 Prednisolone acetate Phase 4,Phase 2,Phase 3
34 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
36 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
39 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
40 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
41 Neuroprotective Agents Phase 4,Phase 2,Phase 3
42 Antiemetics Phase 4,Phase 2,Phase 3
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
44 Protective Agents Phase 4,Phase 2,Phase 3
45 Autonomic Agents Phase 4,Phase 2,Phase 3
46 Tin Fluorides Phase 4
47
belimumab Approved Phase 3 356547-88-1 5957 10451420
48
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
49 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibodies, Antineutrophil Cytoplasmic Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
4 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
5 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Suspended NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
9 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
10 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
11 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
12 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
13 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
14 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
15 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
16 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
17 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
18 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
19 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
20 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
21 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
22 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab
23 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
24 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
25 Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
26 Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies Recruiting NCT03385668 Phase 2 Pirfenidone
27 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
28 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
29 BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
30 CellCept in p-ANCA Vasculitis Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
31 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
32 Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
33 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
34 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
35 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01613599 Rituximab
36 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
37 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
38 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
39 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
40 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
41 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
42 Impact of Vasculitis on Employment and Income Completed NCT02476292
43 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
44 Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Recruiting NCT00315393
45 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis Recruiting NCT02474888
46 Pediatric Vasculitis Initiative Recruiting NCT02006134
47 One-Time DNA Study for Vasculitis Recruiting NCT01241305
48 VCRC Tissue Repository Recruiting NCT02967068
49 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
50 Vasculitis Pregnancy Registry Recruiting NCT02593565

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

41
Neutrophil, Skin, Kidney, Lung, Bone, Heart, Prostate

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 504)
# Title Authors Year
1
A case of microscopic polyangiitis presenting with acute spinal subdural hemorrhage. ( 29971213 )
2018
2
Microscopic polyangiitis necrotizing glomerulonephritis associated with pregnancy: case with a 20-year clinical course and review of the literature. ( 29869147 )
2018
3
Microscopic polyangiitis presented with biopsy-confirmed pleuritis. ( 29927196 )
2018
4
Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States. ( 29470835 )
2018
5
Necrosis of the gastrocnemius muscle in microscopic polyangiitis. ( 29374653 )
2018
6
Tuberculosis and Microscopic Polyangiitis. A Rare Combination. ( 29798821 )
2018
7
Contrast Enhanced Computed Tomography Revealed Gallbladder Hemorrhage Due to Active Vasculitis in a Patient With Microscopic Polyangiitis. ( 29561470 )
2018
8
Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. ( 29621352 )
2018
9
Mean platelet volume can estimate the current vasculitis activity of microscopic polyangiitis. ( 29556749 )
2018
10
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A<sub>2</sub> receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. ( 29792176 )
2018
11
The evaluation of mean platelet volume in microscopic polyangiitis: methodological drawbacks. ( 29974185 )
2018
12
Chorea and Calcifications: Atypical Presentation of Microscopic Polyangiitis. ( 29976382 )
2018
13
Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 29419474 )
2018
14
Ruptured renal artery in microscopic polyangiitis: a case report and literature review. ( 29951966 )
2018
15
From fibrosis to diagnosis: a paediatric case of microscopic polyangiitis and review of the literature. ( 29294176 )
2018
16
Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. ( 30453935 )
2018
17
Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. ( 30236485 )
2018
18
No overlap between IgG4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: a retrospective monocentric study. ( 30552533 )
2018
19
Microscopic polyangiitis and interstitial lung disease. ( 30001894 )
2018
20
The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis. ( 28880680 )
2018
21
Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis
. ( 30106365 )
2018
22
Mycobacterium Kansasii Infection and Microscopic Polyangiitis: An Unexpected Association. ( 30131924 )
2018
23
Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. ( 30175162 )
2018
24
Clinical role of albumin to globulin ratio in microscopic polyangiitis: a retrospective monocentric study. ( 30218289 )
2018
25
Microscopic polyangiitis after streptococcal pharyngitis in a young woman. ( 30282781 )
2018
26
Remission of Microscopic Polyangiitis Using Traditional Chinese Medicine: A Case Report. ( 30340995 )
2018
27
Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy. ( 30404112 )
2018
28
Rupture of Multiple Hepatic Artery Microaneurysms in Microscopic Polyangiitis. ( 30504480 )
2018
29
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. ( 28733791 )
2017
30
IgM Antibodies to Proteinase 3 in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 28076879 )
2017
31
Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. ( 28569178 )
2017
32
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. ( 28905856 )
2017
33
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. ( 28838824 )
2017
34
Noninfective endocarditis in microscopic polyangiitis: Report of a case with a successful response to immunosuppressive therapy. ( 28822626 )
2017
35
The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study. ( 28498830 )
2017
36
Microscopic polyangiitis: Atypical presentation with extensive small bowel necrosis, diffuse alveolar hemorrhage, and renal failure. ( 28348948 )
2017
37
A Case of Microscopic Polyangiitis with Subarachnoid Hemorrhage and Cardiovascular Complications. ( 29142188 )
2017
38
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
39
Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery: A Case Report and Review of the Literature. ( 29293114 )
2017
40
Silicosis, then microscopic polyangiitis-antineutrophil cytoplasmic antibodies-associated vasculitis may be work-related disease in patients with silicosis. ( 29264045 )
2017
41
Gallbladder bleeding associated with microscopic polyangiitis: a case report. ( 28852465 )
2017
42
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial. ( 28678392 )
2017
43
Differential Expression of Toll-Like Receptor Signaling Pathway Is Associated with Microscopic Polyangiitis in Peripheral Blood Neutrophils. ( 28375762 )
2017
44
Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis. ( 28575531 )
2017
45
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? ( 29165307 )
2017
46
Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. ( 28539536 )
2017
47
Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. ( 29082297 )
2017
48
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. ( 28422001 )
2017
49
Microscopic polyangiitis with dermatomyositis. ( 29308288 )
2017
50
Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis. ( 28616269 )
2017

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

Pathways related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 FCGR3B HLA-B HLA-DRB1 IL10 MPO TNF
2
Show member pathways
13.03 HLA-B HLA-DRB1 IL10 TNF
3
Show member pathways
12.49 HLA-B HLA-DRB1 TNF
4
Show member pathways
12.47 HLA-B HLA-DRB1 IL10 TNF
5
Show member pathways
12.34 HLA-DRB1 IL10 TNF
6
Show member pathways
12.3 HLA-DRB1 IL10 TNF
7
Show member pathways
12.28 IL10 MPO TNF
8 12.25 IL10 MPO TNF
9
Show member pathways
12.2 FCGR3B HLA-B TNF
10 12.09 HLA-B HLA-DRB1 TNF
11
Show member pathways
11.96 HLA-B IL10 TNF
12 11.96 HLA-B HLA-DRB1 TNF
13
Show member pathways
11.83 FCGR3B HLA-DRB1 IL10 TNF
14 11.71 FCGR3B HLA-DRB1 IL10 TNF
15 11.64 IL10 MPO TNF
16 11.51 IL10 TNF
17 11.49 IL10 TNF
18 11.4 FCGR3B IL10 TNF
19 11.3 IL10 TNF
20 11.29 IL10 TNF
21 11.27 MPO TNF
22 11.25 FCGR3B HLA-DRB1 IL10
23 11.11 FCGR3B HLA-B HLA-DRB1 MPO
24 11.08 IL10 TNF
25 11.07 IL10 TNF
26 10.66 MPO TNF
27 10.59 HLA-DRB1 IL10 TNF

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.96 HLA-B HLA-DRB1
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.62 HLA-B HLA-DRB1

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.75 FCGR3B HLA-B MPO
2 defense response to bacterium GO:0042742 9.63 IL10 MPO TNF
3 interferon-gamma-mediated signaling pathway GO:0060333 9.57 HLA-B HLA-DRB1
4 response to glucocorticoid GO:0051384 9.56 IL10 TNF
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.55 IL10 TNF
6 antigen processing and presentation GO:0019882 9.54 HLA-B HLA-DRB1
7 negative regulation of T cell proliferation GO:0042130 9.52 HLA-DRB1 IL10
8 negative regulation of mitotic cell cycle GO:0045930 9.51 IL10 TNF
9 negative regulation of interferon-gamma production GO:0032689 9.49 HLA-DRB1 IL10
10 negative regulation of interleukin-6 production GO:0032715 9.48 IL10 TNF
11 positive regulation of cytokine secretion GO:0050715 9.43 IL10 TNF
12 regulation of synapse organization GO:0050807 9.4 IL10 TNF
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.37 IL10 TNF
14 immune response GO:0006955 9.35 FCGR3B HLA-B HLA-DRB1 IL10 TNF
15 endothelial cell apoptotic process GO:0072577 9.32 IL10 TNF
16 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 IL10 TNF
17 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
18 negative regulation of growth of symbiont in host GO:0044130 8.8 IL10 MPO TNF

Molecular functions related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-DRB1

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....